Literature DB >> 12173056

[Cochlear and vestibular risk at high altitude].

K Mees1, M Suckfüll.   

Abstract

Exposure to lowered oxygen pressure at high altitude results in various physiological reactions. The most important response besides hyperventilation is the elevation of the oxygen transport capacity, which simply is achieved by plasma diuresis. Hemoconcentration however not only increases oxygen uptake but also raises blood viscosity, serum osmolality and impairs blood flow. Various observations have suggested that hearing and postural properties deteriorate under these conditions at high altitude. Studies in hypobaric chambers and our own data indicate that the elevated hematocrit levels and hypoxemia may impair the central nervous system functions, resulting in altered speech discrimination, directional hearing, and postural control. However, there is no evidence that cochlear and vestibular sensory cells are affected, whether by acute hypoxia, nor by elevated hematocrit levels up to 58 %. Even an greater increase in serum osmolality or an impaired osmoregulation may not interfere with the outer hair cell function resulting in threshold shift and hearing loss.

Entities:  

Mesh:

Year:  2002        PMID: 12173056     DOI: 10.1055/s-2002-33290

Source DB:  PubMed          Journal:  Laryngorhinootologie        ISSN: 0935-8943            Impact factor:   1.057


  3 in total

1.  Folic acid improves inner ear vascularization in hyperhomocysteinemic mice.

Authors:  Soumi Kundu; Charu Munjal; Neetu Tyagi; Utpal Sen; Aaron C Tyagi; Suresh C Tyagi
Journal:  Hear Res       Date:  2011-12-24       Impact factor: 3.208

2.  A pilot study comparing hearing thresholds of soldiers at induction and after completion of one year in high altitude area.

Authors:  Sachin Saini; Amit Sood; Narendra Kotwal; Atul Kotwal; T K Gupta
Journal:  Med J Armed Forces India       Date:  2021-08-20

Review 3.  Ear, nose, and throat effects of high altitude.

Authors:  Cemal Cingi; Alper Nabi Erkan; Gerhard Rettinger
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-06-24       Impact factor: 2.503

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.